ACADEMISCH ZIEKENHUIS MAASTRICHT Patent applications |
Patent application number | Title | Published |
20140194309 | IN VITRO METHOD FOR PREDICTING IN VIVO GENOTOXICITY OF CHEMICAL COMPOUNDS - The invention is in the field of genomics and it provides an in vitro method for predicting whether a compound is genotoxic in vivo. In particular, the invention provides a method for predicting the in vivo genotoxicity of a compound comprising the steps of performing an Ames test on the compound and determining if the result is positive or negative, followed by a step wherein the gene expression of at least 3 genes is determined in a HepG2 cell, compared to a reference value and predicting that the compound is in vivo genotoxic if the expression level of more than 2 of the genes is above a reference value. | 07-10-2014 |
20140162978 | METHOD FOR THE PREVENTION AND TREATMENT OF SEPSIS - This invention is in the field of medical treatment, in particular the invention provides a method for the prevention and treatment for sepsis or septic shock. The invention provides a novel use of a known medicament, i.e. pentasaccharide-depleted heparin for use in the treatment or prevention of sepsis, SIRS, severe sepsis or septic shock. | 06-12-2014 |
20130316924 | METHOD FOR DETERMINING THE NEURODEVELOPMENTAL TOXICITY OF A COMPOUND IN VITRO - This invention is in the field of medical molecular diagnostics. It provides methods and means for the in vitro detection of the neurodevelopmental toxicity of a compound by determining the gene expression of a limited number of genes. More in particular, it relates to a method for determining the likelihood that a compound is neurodevelopmental toxic, comprising the steps of: providing embryonic stem cells, allowing the stem cells to form embryoid bodies, allowing the embryoid bodies to differentiate into neural cells, in the presence of said compound, thereby creating a neural differentiation culture, extracting total RNA from the cells in said neural differentiation culture, determining the expression levels of genes Hoxb6, Nrk, 1700011H14Rik and Tph1, comparing the expression levels with a predetermined reference value and determining the increase or decrease of the expression level relative to the reference value, wherein a relative increase or decrease in expression value of more than 20% indicates that a compound is neurodevelopmental toxic. | 11-28-2013 |
20130244896 | IN VITRO METHOD FOR PREDICTING WHETHER A COMPOUND IS GENOTOXIC IN VIVO - The invention is in the field of genomics and it provides an in vitro method for predicting whether a compound is genotoxic in vivo. It provides a method that employs the analysis of expression profiles of microRNAs in cells exposed to a potentially genotoxic compound. It was found that differential expression of a number of microRNAs could reliably predict whether a compound was a genotoxic or a non-genotoxic compound. | 09-19-2013 |
20120203289 | CRANIAL IMPLANT - An implant, such as a cranial implant, for attachment to a defect in a bone structure having an edge is described. The implant comprises a direction of extension and a rim extending substantially perpendicular to the direction of extension of the implant. The rim is configured to be attached to the edge of the bone structure and comprises at least one mounting portion configured to accommodate a fastener such that at least a portion of the fastener is extendible in a direction extending away from the rim at an angle which is at most acute with respect to the direction of extension of the implant. The implant is configured such that upon placing the implant in the defect, the fastener is extendible into the edge of the bone defect in a controllable manner. | 08-09-2012 |
20120141442 | MEANS AND METHODS FOR COUNTERACTING, DELAYING AND/OR PREVENTING ADVERSE ENERGY METABOLISM SWITCHES IN HEART DISEASE - The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease. | 06-07-2012 |
20120014876 | ANTAGONISTIC PEPTIDES FOR FRIZZLED-1 AND FRIZZLED-2 - The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled 1 and/or frizzled 2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue. | 01-19-2012 |
20110250606 | METHOD FOR THE IDENTIFICATION OF CARCINOGENIC COMPOUNDS - The present invention relates to methods for the identification of genotoxic carcinogenic compounds. In particular, a method is disclosed for the identification of genotoxic carcinogenic compounds wherein a eukaryotic cell is exposed to a potentially genotoxic compound in a culture medium where after samples are taken from the cell and/or the culture medium at at least one predetermined time point which samples are then analysed for increased or decreased expression levels of at least three DNA repair genes as compared to a control cell that is not exposed to the carcinogenic compound. | 10-13-2011 |
20110230357 | METHOD FOR DETERMINING THE PRIMARY SITE OF CUP - The invention relates to a method for the classification of cancer using a specific multi-class tumor classifier comprising specific sets of genes for the interpretation of expression data obtained from tumor samples. More specifically, the method of the present invention provides an accurate, reproducible, robust, objective and easy to perform method for determining the primary site of a Cancer of Unknown Primary site (CUP). For this purpose, the method provides that a classifier parameter is determined by comparing an expression profile of a tumor sample with a template profile representative for a particular primary site of a cancer. | 09-22-2011 |